BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial

Reuters

08 Apr

BRIEF-<a href="https://laohu8.com/S/RNAC">Cartesian Therapeutics</a>’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial

April 8 (Reuters) - Cartesian Therapeutics Inc RNAC.O:

CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIAL
CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25
CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATION

Source text: ID:nGNX26N9Dk

Further company coverage: RNAC.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2525898674"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525898674\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2525898674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525898674","market":"nz","top_or_hot":-1,"title":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a>’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial</title></head><body><p><span>April 8 (Reuters)</span><span> - </span>Cartesian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>RNAC.O</span>:</p><ul><li><p>CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIAL</p></li><li><p>CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25</p></li><li><p>CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATION</p></li></ul><p>Source text: <span>ID:nGNX26N9Dk</span></p><p>Further company coverage: <span>RNAC.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-08 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a>’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis Trial</title></head><body><p><span>April 8 (Reuters)</span><span> - </span>Cartesian <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>RNAC.O</span>:</p><ul><li><p>CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIAL</p></li><li><p>CARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25</p></li><li><p>CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATION</p></li></ul><p>Source text: <span>ID:nGNX26N9Dk</span></p><p>Further company coverage: <span>RNAC.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM057:1","article_id":"2525898674","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525898674","pubTimestamp":1744110272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis TrialApril 8 (Reuters) - Cart","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RNAC":"Cartesian Therapeutics"},"translate_title":"BRIEF-Cartesian Therapeutics的Descartes-08在2B期重症肌无力试验中单疗程治疗后至第12个月可提供深度和持续的益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":0.9},"content_text":"BRIEF-Cartesian Therapeutics’ Descartes-08 Observed To Provide Deep And Sustained Benefits Through Month 12 After A Single Course Of Therapy In Phase 2B Myasthenia Gravis TrialApril 8 (Reuters) - Cartesian Therapeutics Inc RNAC.O:CARTESIAN THERAPEUTICS’ DESCARTES-08 OBSERVED TO PROVIDE DEEP AND SUSTAINED BENEFITS THROUGH MONTH 12 AFTER A SINGLE COURSE OF THERAPY IN PHASE 2B MYASTHENIA GRAVIS TRIALCARTESIAN THERAPEUTICS INC - PHASE 3 AURORA TRIAL ON TRACK TO DOSE FIRST PATIENT IN 2Q25CARTESIAN THERAPEUTICS-SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND CONTINUES TO SUPPORT OUTPATIENT ADMINISTRATIONSource text: ID:nGNX26N9DkFurther company coverage: RNAC.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}